← All trials
NCT06847724
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 14, 2025
- Primary completion
- May 14, 2027
- Completion date
- Oct 14, 2029
- First posted
- Feb 26, 2025
- Last posted
- Feb 26, 2025
- Enrollment
- 518
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- SandozLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.